Skip to main content
OpenTrials

Clinical trial condition

Melanoma Stage III

Explore clinical trials studying Melanoma Stage III. Study availability and eligibility vary by location and protocol.

35 public trials 16 recruiting studies
Refine in advanced search Browse all conditions

Melanoma Stage III trial results

Completed

A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Advanced Melanoma That Has Not Responded to Other Forms of Treatment

NCT04526899

Conditions
Melanoma, Melanoma Stage III, Melanoma Stage IV, +12 more
Locations
  • University Of Arizona College Of Medicine Tucson, Arizona, United States
  • University of California, San Francisco: Helen Diller Family Comprehensive Cancer Center San Francisco, California, United States
  • Sylvester Comprehensive Cancer Center/ UMHC Miami, Florida, United States
  • Oncology Hematology West P.C. dba Nebraska Cancer Specialists Omaha, Nebraska, United States
View all 49 locations
View Trial Details
Active, Not Recruiting

CD8+ T Cell Imaging During Pre-surgery Immunotherapy in People With Melanoma

NCT05289193

Conditions
Melanoma, Melanoma Stage III, Neoplasms, +10 more
Locations
  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities) Middletown, New Jersey, United States
  • Memorial Sloan Kettering Westchester (Limited Protocol Activities) Harrison, New York, United States
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities) New York, United States
View Trial Details
Active, Not Recruiting

SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab

NCT03161431

Conditions
Melanoma, Melanoma Stage III, Melanoma Stage IV, +11 more
Locations
  • University of Miami Miami, Florida, United States
  • Massachusetts General Hospital Cancer Center Boston, Massachusetts, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Mayo Clinic Rochester, Minnesota, United States
View Trial Details
Active, Not Recruiting

SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)

NCT04079166

Conditions
Malignant Melanoma, Melanoma, Melanoma (Skin), +13 more
Locations
  • Cambridge University Hospitals NHS Foundation Trust Cambridge, United Kingdom
  • Velindre University NHS Trust Cardiff, United Kingdom
  • The Leeds Teaching Hospitals NHS Trust Leeds, United Kingdom
  • Guy's & St Thomas' NHS Foundation Trust London, United Kingdom
View all 15 locations
View Trial Details

Related conditions